ETFs & Funds
This user currently has no profile.
Jagdish Gohil, DPCS, He Leads Information Technology & Administration and is responsible for Data Mining and Statistical Analysis work. Prior to joining MP Advisors, he has worked with one of the leading logistics company in India, as Systems Executive where he was responsible for their MIS
Independent / boutique research firm analyst.
Stocks - long, Stocks - short
MP Advisors is an Independent equity investment research company with sole focus on the Pharmaceutical, Biotech and Healthcare sector. Formerly it was the affiliate of Mehta Partners LLC, New York. Our research products are written by experienced team of analysts who maintain rapport with physicians, CSO,
research scientists, medical representatives, distributors, biostatistician, ministry of health (e.g. MHLW in Japan) etc. MP Advisors is in the business since early 90s and have developed close relationship with company managements. MP has data going back to 1980s. MP Advisors provide an in-depth analysis and information on more than 200 Pharma and Biotech companies across the globe (US, EU, Japan and India) including but not limited to Pfizer, Merck, Novartis, Roche, Dr. Reddy’s, Ranbaxy, Gilead, Amgen, Allos, Ablynx, Micromet, Protalix, Takeda, Torii, Aveo etc. In addition to this, its reports and data base on Para IV litigations, specific disease/therapy class backed by views of clinical experts, molecular biologists etc. (e.g. Oral anticoagulants, Hepatitis C, Obesity, Lupus, Chronic Obstructive Inflammatory Diseases, Acute Coronary Syndrome, Biosimilar etc..), Japan generic, Sales trend analysis in Japan (branded), branded generics in India and emerging markets, major medical conference coverage [AASLD, ARVO, ATS, ASCO, ACC, ADA, ACR, ICAD (Alzheimer’s), WPC (Parkinson), EASD, EASL, ESC etc], API industry in China and India are some of MP’s competitive strengths.
Currently, there are no blog details for gohilj.
Currently, there are no book details for gohilj.
The war over Lipitor - Ranbaxy Quality The war over Lipitor - Ranbaxy Quality Problems Lead to Market Chaos Comment or flag »
May 12, 2011